Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose-dependent Insulinotropic Polypeptide (GIP)
- Target
- GIP
- Molecular classification
- Peptide Hormone, Incretin, Secretin Family
01
Overview
Glucose-dependent insulinotropic polypeptide (GIP), also known as gastric inhibitory polypeptide, is a 42-amino acid peptide hormone that acts as an incretin. It stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner. It also modulates glucagon secretion and promotes adipogenesis. GIP exerts pleiotropic effects beyond glycemic control including promoting growth and survival of pancreatic beta-cells, influencing brain function, bone metabolism, cardiovascular system regulation, and gastrointestinal tract physiology. Targeting the GIP-GIPR axis is being investigated for treating type 2 diabetes mellitus (T2DM) and obesity.
- Other names
- Gastric Inhibitory Polypeptide
02
Mechanism of action
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner; modulates glucagon secretion; promotes fat deposition in adipose tissue.
03
Biological functions
Stimulates insulin secretionModulates glucagon secretionPromotes adipogenesisPromotes beta-cell growth and survivalReduces beta-cell apoptosisInfluences brain functionInfluences bone metabolismCardiovascular system regulationGastrointestinal tract physiology
04
Disease associations
Type 2 Diabetes MellitusObesity
05
Safety considerations
Potential for excessive adipogenesisPotential for hypoglycemia with GIPR agonists
06
Interacting drugs
DPP-IV inhibitors
3 more in the full profile.
07
Biomarkers
GIP levels
Beyond the preview
Go deeper on Glucose-dependent Insulinotropic Polypeptide (GIP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glucose-dependent Insulinotropic Polypeptide (GIP).